Nurix Therapeutics Awarded Innovation Passport for Entry into Innovative Licensing and Access…
NX-1607 is being evaluated in multiple immuno-oncology indications, including a range of solid tumor types The ILAP aims to accelerate the time to market for innovative medicines that address the needs of patients with life-threatening or…